Triglav Skladi D.O.O. Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Triglav Skladi D.O.O. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 16,000 shares of the biopharmaceutical company's stock, valued at approximately $1,478,000.

Several other large investors have also made changes to their positions in the business. Norges Bank purchased a new position in Gilead Sciences in the 4th quarter valued at $1,789,254,000. FMR LLC lifted its holdings in Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock valued at $594,370,000 after purchasing an additional 5,653,075 shares in the last quarter. Northern Trust Corp lifted its holdings in Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Gilead Sciences in the 4th quarter valued at $207,340,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 1.3%

NASDAQ GILD traded down $1.39 on Wednesday, reaching $107.72. The company had a trading volume of 7,958,565 shares, compared to its average volume of 7,713,999. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a 50 day moving average of $105.44 and a two-hundred day moving average of $100.07. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market cap of $134.00 billion, a price-to-earnings ratio of 291.14, a P/E/G ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the firm earned ($1.32) EPS. The firm's revenue for the quarter was down .3% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at approximately $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 22,929 shares of company stock worth $2,634,220 in the last three months. Corporate insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Bank of America raised their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Royal Bank of Canada raised their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. Oppenheimer cut their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, BMO Capital Markets raised their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $110.55.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.